TP53 and acute myeloid leukemia: The restoration of its activity through inhibition of the E3 ubiquitin-protein ligase binding to p53 (MDM2) has been extensively studied in the past years, as pharmacological intervention against AML that retains wild-type (wt) p53 [37,38,39].